Location: Home > Scientists
  Principal Investigators
Name:
 Hezhe Lu
Subject:
 Pathology and Pathophysiology
Tel/Fax:
 +86-10-6480 7150  / 
E-mail:
 Hezhe@ioz.ac.cn
Address:
 he State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Building of Institute for Stem Cell and Regeneration, CAS, Yard A 3, Datun Road, Chaoyang District, Beijing 100101, P.R.China
More:
 Group of Cell heterogeneity and fate determination      
Resume:
Education:
2006-2011: PH.D. in Key Laboratory of Cell Proliferation and Regulation Biology of Ministry of Education, Beijing Normal University
2002-2006: B.S. in College of Life Sciences, Beijing Normal University
Employment:
2011-2016: Postdoctoral Fellow, Department of Biology, University of Pennsylvania
2016-2020: Postdoctoral Fellow, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital

Research Interests:
1 Development of computational models and investigation of rare cancer cells variability and drug-induced reprogramming.
2 Investigation of single cell fate reprogramming by oncogene activation.
3 Small molecule screens to identify potential drug promoting T cell infiltration into solid tumor.

Awards and Honors:

Professional Activities:

Research Grants:

Selected Publications:
  1. Hezhe Lu, Shujing Liu, Gao Zhang, Bin Wu, Yueyao Zhu, Dennie T. Frederick, Yi Hu, Wenqun Zhong, Sergio Randell, Norah Sadek, Wei Zhang, Gang Chen, Chaoran Cheng, Jingwen Zeng, Lawrence Wu, Jie Zhang, Xiaoming Liu, Wei Xu, Clemens Krepler, Katrin Sproesser, Min Xiao, Benchun Miao, Jianglan Liu, Claire D. Song, Jephrey Y. Liu, Giorgos C. Karakousis, Lynn M. Schuchter, Yiling Lu, Gordon Mills, Yusheng Cong, Jonathan Chernoff, Jun Guo, Genevieve M. Boland, Ryan J. Sullivan, Zhi Wei, Jeffrey Field, Ravi K. Amaravadi, Keith T. Flaherty, Meenhard Herlyn*, Xiaowei Xu*, Wei Guo*  PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature (2017) 550(7674):133-136.   
  2. Hezhe Lu, Shujing Liu, Gao Zhang, Lawrence N. Kwong, Yueyao Zhu, John P. Miller, Yi Hu, Wenqun Zhong, Jingwen Zeng, Lawrence Wu, Clemens Krepler, Katrin Sproesser, Min Xiao, Wei Xu, Giorgos C. Karakousis, Lynn M. Schuchter, Jeffery Field, Paul J. Zhang, Meenhard Herlyn, Xiaowei Xu*, Wei Guo* Oncogenica BRAF-induced invadopodia formation and melanoma invasion. Cell Reports. (2016) 15(9): 2012–2024.  
  3. Hezhe Lu, Jianglan Liu, Shujing Liu, Jingwen Zeng, Deqiang Ding, Russ P. Carstens, Yusheng Cong, Xiaowei Xu and Wei Guo* Exo70 isoform switching upon Epithelial-Mesenchymal transition mediates cancer cell invasion. Developmental Cell. (2013) 27(5): 560-573.  
  4. Hezhe Lu, Ellen Fan, Suozhu Sun, Xiaoxiao Ma, Xiaoyan Zhang, David M.K. Han, and Yu-Sheng Cong* Cyr61 Is Up-Regulated in Prostate Cancer and Associated With the p53 Gene Status. J Cell Biochem. (2009) 106 (4): 738-744. 
  5. Shujing Liu, Suresh M Kumar, Hezhe Lu, Aihua Liu, Ruifeng Yang, Anitha Pushparajan, Wei Guo and Xiaowei Xu* MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1–Snail1 pathway in melanoma. Journal of Pathology. (2012) 226: 61–72.
  6. Suresh M Kumar, Shujing Liu, Hezhe Lu, Hongtao Zhang, Paul J. Zhang, Phyllis A. Gimotty, Matthew Guerra, Wei Guo and Xiaowei Xu* Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. (2012) Oncogene. 31(47):4898-91.1
  7. Claude C Warzecha, Peng Jiang, Karine Amirikian, Kimberly A Dittmar, Hezhe Lu, Shihao Shen, Wei Guo, Yi Xing and Russ P Carstens* An ESRP-regulated splicing programme is abrogated during the epithelial–mesenchymal transition. EMBO J. (2010) 29 (19):3286-3300.